Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Mirum Pharmaceuticals, Inc. - common stock (NQ:MIRM)

97.64 +1.33 (+1.38%)

Streaming Delayed Price Updated: 3:51 PM EDT, Aug 24, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	230,363
Open	96.31
Bid (Size)	97.61 (100)
Ask (Size)	97.77 (500)
Prev. Close	96.31
Today's Range	95.49 - 97.85
52wk Range	63.23 - 130.00
Shares Outstanding	38,297,975
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Mirum Pharmaceuticals (MIRM) Q2 2026 Earnings Call Transcript ↗

August 12, 2026

LIVMARLI sales surged 46% while management raised full-year guidance to $680M–$700M.

Via The Motley Fool

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 11, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Performance

YTD	+25.1%	+25.1%
1 Month	-13.6%	-13.6%
3 Month	-1.3%	-1.3%
6 Month	-7.8%	-7.8%
1 Year	+36.0%	+36.0%

More News

Mirum Pharmaceuticals Q2 Earnings Call Highlights ↗

August 05, 2026

Via MarketBeat

Mirum Pharmaceuticals (NASDAQ:MIRM) Slides on Wider Loss and Volixibat Delay Despite Revenue Beat ↗

August 05, 2026

Via Chartmill

Mirum Pharmaceuticals (NASDAQ:MIRM) Stock Dips After Q1 Revenue Beat and Guidance Raise, Despite Massive IPR&D Charge ↗

May 06, 2026

Via Chartmill

Wondering what's happening in today's after-hours session? ↗

August 05, 2026

Via Chartmill

Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

August 05, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026

July 29, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 13, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva

June 14, 2026

From Mirum Pharmaceuticals, Inc. and Incyte

Via Business Wire

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 11, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026

June 04, 2026

From Mirum Pharmaceuticals, Inc. and Incyte

Via Business Wire

Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026

May 30, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Enters Catalyst-Rich Stretch as LIVMARLI Sales and Pipeline Advance ↗

May 27, 2026

Via MarketBeat

Mirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026

May 21, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharma: A Rare Disease Growth Story to Watch ↗

May 20, 2026

Via MarketBeat

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 14, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes

May 12, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering

May 12, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

May 12, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Penn Capital Unloads 1.13 Million RealReal Shares Following Massive Stock Run-Up ↗

May 07, 2026

Via The Motley Fool

Mirum (MIRM) Q1 2026 Earnings Call Transcript ↗

May 06, 2026

Via The Motley Fool

Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

May 06, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Announces Primary Endpoint Met in VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis

May 04, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026

May 03, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Frequently Asked Questions

Is Mirum Pharmaceuticals, Inc. - common stock publicly traded?

Yes, Mirum Pharmaceuticals, Inc. - common stock is publicly traded.

What exchange does Mirum Pharmaceuticals, Inc. - common stock trade on?

Mirum Pharmaceuticals, Inc. - common stock trades on the Nasdaq Stock Market

What is the ticker symbol for Mirum Pharmaceuticals, Inc. - common stock?

The ticker symbol for Mirum Pharmaceuticals, Inc. - common stock is MIRM on the Nasdaq Stock Market

What is the current price of Mirum Pharmaceuticals, Inc. - common stock?

The current price of Mirum Pharmaceuticals, Inc. - common stock is 97.64

When was Mirum Pharmaceuticals, Inc. - common stock last traded?

The last trade of Mirum Pharmaceuticals, Inc. - common stock was at 08/24/26 03:51 PM ET

What is the market capitalization of Mirum Pharmaceuticals, Inc. - common stock?

The market capitalization of Mirum Pharmaceuticals, Inc. - common stock is 3.74B

How many shares of Mirum Pharmaceuticals, Inc. - common stock are outstanding?

Mirum Pharmaceuticals, Inc. - common stock has 4B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.